



Australia, 2015

Global Vaccine Action Plan (GVAP) and Regional framework indicators

Polio-free status sustained	Yes	At least one dose of IPV introduced by end of 2015	Yes
Country achieved MNT elimination	Yes	Increasing trend in domestic expenditure since 2010	No data
Country verified for measles elimination	Yes	NITAG established (with administrative/legal basis only)	Yes
Seroprevalence of chronic hepatitis B infection (HBsAg) reduced to < 1% in 5 year olds by 2017	Yes	Functional NITAG (legal basis, TORs, ≥ 5 areas of expertise, ≥ 1 meeting per year, agenda and background docs, disclosure of conflict of interest)	Yes
At least one new or underutilized vaccine introduced since 2010*	No	JE vaccine introduced in JE risk areas	Yes (not in RI)
DTP3 national immunization coverage ≥ 95% by 2020	93%	Primary series JE vaccine ≥ 90% coverage among children under 15 years old	No data
DTP3 coverage ≥ 90% in at least 90% of districts (proportion of districts with ≥ 90% coverage)	Yes (100%)	Case-based surveillance for invasive bacterial vaccine-preventable disease	No
Sustained DTP3 coverage ≥ 95% for three or more years	No	Case-based surveillance for rotavirus disease	No
DTP dropout rate < 5%	No data	Rubella and CRS case-based data submitted to WPRO	No

* New or underutilized vaccines include Hib, HPV, PCV and RV. IPV and JE are not counted. Otherwise, "Yes (specified)" is indicated to account for other vaccines.

Population		
	JRF	UN*
Total		23 968 973
Births		317 650
NIP target < 1 year (surviving infants)	308 543	314 448
Source of data for NIP target	Childhood Immunization Register	

* United Nations World Population Prospects: The 2015 Revision

Finance	
Gross national income per capita* (US \$)	\$ 60 070
Line item in budget for vaccines	Yes
% of vaccines in routine immunization funded by government	100%
% of routine immunization - funded by government	100%
Eligible for GAVI support	No

* World Bank Open Data

Reported cases of selected vaccine preventable diseases


Year	Acute flaccid paralysis (AFP)		Measles		Rubella		Congenital rubella syndrome (CRS)		Neonatal tetanus		Total tetanus		Diphtheria		Pertussis	
	Non-polio AFP rate	% adequate specimens	Cases	IR	Cases	IR	Cases	IR	Cases	IR	Cases	IR	Cases	IR	Cases	IR
2011	1.5	34%	190	8.4	60	2.7	0	0.0	0	0.0	3	0.0	4	0.0	38 040	168.3
2012	1.3	29%	199	8.7	35	1.5	1	0.0	0	0.0	7	0.0	0	0.0	23 855	104.1
2013	1.4	39%	158	6.8	26	1.1	2	0.0	0	0.0	4	0.0	1	0.0	12 319	52.8
2014	1.4	50%	340	14.4	17	0.7	0	0.0	0	0.0	3	0.0	2	0.0	11 842	50.1
2015	1.2	26%	74	3.1	18	0.8	1	0.0	0	0.0	3	0.0	2	0.0	22 508	93.9

Non-polio AFP rate = incidence per 100 000 under 15 years; % adequate specimens = % of AFP cases with 2 specimens within 14 days of paralysis onset
 IR = incidence rate: for measles and rubella, per 1 000 000 population; for CRS and neonatal tetanus, per 1000 live births; for all others, per 100 000 population. Total tetanus includes neonatal tetanus cases.
 Population source: United Nations World Population Prospects


Invasive bacterial disease, rotavirus and japanese encephalitis

Year	Rotavirus diarrhea		Japanese encephalitis		Bacterial meningitis		Bacterial pneumonia	
	Surveillance system type	Confirmed cases	Surveillance system type	Confirmed cases	Surveillance system type	Confirmed cases	Surveillance system type	Confirmed cases
2013	Sentinel (5 sites)	2907	Nationwide	4	Nationwide	Pneumo - 70	Nationwide	Pneumo - 837
2014	Sentinel (6 sites)	3013	Nationwide	1	Nationwide	Pneumo - 115	Nationwide	Pneumo - 695
2015	Sentinel (16 sites)	4093	Nationwide	3	Nationwide	Pneumo - 114	Nationwide	Pneumo - 740

Confirmed measles cases by month of onset 2011–2015



Confirmed measles cases by age group and vaccination status, 2014–2015





Australia, 2015

Immunization schedule									
DTP-Hib-HepB-IPV	M2, M4, M6	HepB	B	Varicella	Y10-15	Hib-MenC	M12	Pneumo_conj	M2, M4, M6, M12, M12-18
Rotavirus	M2, M4, M6	MMR	M12	Tdap	Y10-15	DTP-IPV	Y4	Pneumo_ps	Y4, Y15, Y50, Y65
Influenza	M6+, Y3+	MMRV	M18	HPV	Y10-15				



B=birth, W=week, M=month, Y=year

Planning	
Multi-year plan (MYP)	Yes (2013-2018)
Annual workplan for immunization activities	Yes
Updated wild poliovirus importation and cVDPV response plan	No

NIP priority needs
1. Improve immunization coverage
2. Ensure secure vaccine supply and efficient use of vaccines from the National Immunization Program
3. Continue to enhance vaccine safety monitoring systems

Safe immunization	
% districts using auto-disable syringes	
System to monitor AEFI	Yes
Number of AEFI	3294
Injection safety policy implemented	Yes
Disposal methods	Incineration, Other
Injection safety review	Yes (National)

Delivery of immunization services	
% of population served by outreach	
No. (%) of districts with DTP3 coverage < 80%	0 (0%)
No. (%) of districts with DTP3 coverage ≥ 90%	8 (100%)
No. (%) of districts with MCV1 coverage < 80%	0 (0%)
No. (%) of districts with MCV1 coverage ≥ 90%	8 (100%)
No. (%) of districts with DTP drop-out > 10%	0 (0%)
No. (%) of districts with DTP1–MCV1 drop-out > 10%	0 (0%)



School-based immunization	
Is there a school entry requirement?	Yes
If no, do schools check immunization status at enrolment?	
What vaccines are required/checked?	Pre-school/Primary - HepB, DTpa, Hib, IPV, 13vPCV, Rotavirus, MMR, Varicella Secondary - Varicella, HPV, dTpa
At what school level/year?	
Is routine vaccination given at school?	Yes
Which vaccination?	Varicella, HPV, dTpa
If yes, is this part of a comprehensive school-health program that delivers other health interventions?	Yes

Surveys		
	Coverage survey	Serosurvey
Most recent (year)	2014	2013
Type		
Geographical representativeness	National	Measles, polio, rubella, mumps
Result		

Measles and rubella elimination			
Confirmed measles case rate* (per 1 million population)	3.3	Year of MCV1 introduction	1970
Confirmed rubella case rate* (per 1 million population)	No data	Year of MCV2 introduction	1994
Discarded as non-measles rate* (Target: ≥ 2 per 100 000 population)	No data	Year of RCV introduction	1989
% suspected cases with adequate specimens* (Target: ≥ 80%)	No data	Surveillance conducted for CRS	Yes (Nationwide)
Imported measles cases*	33	Antigens, year and target population of last SIA	M - 1998 (5-12 yrs)
Measles cases with unknown source of infection*	11	Number vaccinated (SIA coverage)	1 335 000 (75%)

* Data from measles monthly country reports to WHO

Hepatitis B control			
Year HepB3 vaccine introduced nationwide	2000	Systems to deliver HepB vaccine birth dose	
Year HepB birth dose introduced	2000	HBsAg results assessed for blood donors	Yes
HepB birth dose (within 24 hours) coverage		Policy for screening of pregnant women	Yes
HepB birth dose (within and after 24 hours) coverage		Policy to vaccinate health care workers	No